Novartis's Sandoz receives FDA approval for biosimilar Zarxio

Novartis subsidiary Sandoz has received approval from the US Food and Drug Administration (FDA) for its Zarxio (filgrastim-sndz) for all indications included in the reference product's label.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news